KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Intangibles: 2016-2025

Historic Intangibles for Acadia Pharmaceuticals (ACAD) over the last 8 years, with Sep 2025 value amounting to $111.6 million.

  • Acadia Pharmaceuticals' Intangibles rose 5.78% to $111.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.6 million, marking a year-over-year increase of 5.78%. This contributed to the annual value of $119.8 million for FY2024, which is 82.90% up from last year.
  • Acadia Pharmaceuticals' Intangibles amounted to $111.6 million in Q3 2025, which was down 2.38% from $114.3 million recorded in Q2 2025.
  • Acadia Pharmaceuticals' 5-year Intangibles high stood at $119.8 million for Q4 2024, and its period low was $369,000 during Q2 2021.
  • In the last 3 years, Acadia Pharmaceuticals' Intangibles had a median value of $107.9 million in 2024 and averaged $96.0 million.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Intangibles slumped by 80.01% in 2021 and then skyrocketed by 82.90% in 2024.
  • Acadia Pharmaceuticals' Intangibles (Quarterly) stood at $369,000 in 2021, then reached $65.5 million in 2023, then surged by 82.90% to $119.8 million in 2024, then climbed by 5.78% to $111.6 million in 2025.
  • Its Intangibles stands at $111.6 million for Q3 2025, versus $114.3 million for Q2 2025 and $117.1 million for Q1 2025.